Bridge to Life Ltd. said a new National Institute for Health and Care Excellence (NICE) guideline recommends routine National Health Service (NHS) funding for ex situ machine perfusion devices used to preserve livers from deceased donors before transplantation, including its VitaSmart hypothermic oxygenated perfusion (HOPE) system. NICE’s evaluation found advanced perfusion systems offered clear clinical and economic benefits over traditional static cold storage, while HOPE was associated with improved graft survival and fewer biliary complications. The guidance, titled Ex-situ machine perfusion devices to preserve deceased donor livers for transplantation, carries reference HTG780 and was published on Aug. 20, 2026. Bridge to Life issued its corrected press release on Aug. 27, 2026, with Rebeca Sanabria Mateos’s name corrected from Rebecca. CEO and president Don Webber said the recommendation strengthens HOPE’s position in liver transplantation after more than a decade of use in Europe and following the U.S. Food and Drug Administration’s De Novo authorization. VitaSmart delivers an oxygenated solution to donor livers before transplantation and is designed to offer simpler workflows and lower capital requirements than normothermic systems. It is available in the United States, the United Kingdom, Europe, Saudi Arabia, India and countries accepting the CE mark. Bridge to Life’s portfolio also includes Belzer UW®, which the company describes as the global benchmark for static cold storage and the most widely used cold-flush solution in abdominal organ transplantation.